Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 7505195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.

  1993cited by this paper
• Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).

  1992cited by this paper
• Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors.

  1992cited by this paper
• Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.

  1992cited by this paper
• T‐cell recognition of oncogene products: A new strategy for immunotherapy

  1992cited by this paper
• Identification of Heregulin, a Specific Activator of p185erbB2

  1992cited by this paper
• Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses.

  1992cited by this paper
• Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.

  1992influential reference
• ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.

  1992cited by this paper
• Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.

  1992cited by this paper
• Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

  1992cited by this paper
• Presence of circulating anti‐c‐myb oncogene product antibodies in human sera

  1991cited by this paper
• Identifying antigenic T-cell sites

  1991cited by this paper
• Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.

  1991cited by this paper
• The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity.

  1990cited by this paper
• Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

  1990cited by this paper
• Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.

  1990cited by this paper
• Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.

  1989cited by this paper
• Detection of circulating antibodies against c-myc protein in cancer patient sera.

  1988cited by this paper
• A sequence pattern common to T cell epitopes.

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Purification and characterization of the major iron-regulated protein expressed by pathogenic Neisseriae

  1987cited by this paper
• Prediction of immunodominant helper T cell antigenic sites from the primary sequence.

  1987cited by this paper
• The neu oncogene encodes an epidermal growth factor receptor-related protein

  1986cited by this paper

• On-Chip Isolation and Reciprocal Signal Amplification Detection of Tumor-Derived Exosomes in Dual-Control Microfluidic Device.

  2025cites this paper
• Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies

  2024cites this paper
• Redox state associated with antitumor and immunomodulatory peptides in cancer.

  2022cites this paper
• Immunogenicity of a xenogeneic multi-epitope HER2+ breast cancer DNA vaccine targeting the dendritic cell restricted antigen-uptake receptor DEC205.

  2022cites this paper
• Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer

  2022cites this paper
• Breast Cancer Vaccines: Disappointing or Promising?

  2022cites this paper
• Tumor Mutation Burden Prediction Model in Egyptian Breast Cancer patients based on Next Generation Sequencing

  2021cites this paper
• Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy

  2021cites this paper
• The Development of Vaccines from Synthetic Tumor‐Associated Mucin Glycopeptides and their Glycosylation‐Dependent Immune Response

  2021cites this paper
• Can Breast Implants Induce Breast Cancer Immunosurveillance? An Analysis of Antibody Response to Breast Cancer Antigen following Implant Placement

  2021cites this paper
• The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer

  2021cites this paper
• Immune System Efficiency in Cancer and the Microbiota Influence

  2021cites this paper
• Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination

  2021cites this paper
• AE36 HER2/neu-derived Peptide Linked to Positively Charged Liposomes with CpG-ODN as an Effective Therapeutic and Prophylactic Vaccine for Breast Cancer

  2020cites this paper
• Tumor-associated antigens and their antibodies in the screening, diagnosis, and monitoring of esophageal cancers.

  2020cites this paper
• A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response.

  2020cites this paper
• AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence

  2020cites this paper
• HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development

  2020cites this paper
• Targeted Feature Extraction in MALDI Mass Spectrometry Imaging to Discriminate Proteomic Profiles of Breast and Ovarian Cancer

  2019cites this paper
• Breast Cancer and Immunosenescence

  2019cites this paper
• P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer

  2019cites this paper
• Electrochemical biosensors for autoantibodies in autoimmune and cancer diseases

  2019cites this paper
• Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

  2019cites this paper
• Regulation of the translation activity of antigen-specific mRNA is responsible for antigen loss and tumor immune escape in a HER2-expressing tumor model

  2019cites this paper
• Regulation of expression of MLAA-34 gene through transcriptional factors E2F1 and MZF-1.

  2019cites this paper
• Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid

  2018cites this paper
• Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67

  2018cites this paper
• Prediction of tumor mutation burden in breast cancer based on the expression of er, Pr, her-2, and Ki-67

  2018cites this paper
• Multiplexed Autoantibody Signature for Serological Detection of Canine Mammary Tumours

  2018cites this paper
• Characterization of sentinel node-derived antibodies from breast cancer patients.

  2018cites this paper
• Semi-Automatic Analysis for Unidimensional Immunoblot Images to Discriminate Breast Cancer Cases Using Time Series Data Mining

  2018cites this paper
• 13 – Cancer Vaccines

  2018cites this paper
• Novel EXO-T vaccine using polyclonal CD4+ T cells armed with HER2-specific exosomes for HER2-positive breast cancer

  2018cites this paper
• Developing anti‐HER2 vaccines: Breast cancer experience

  2018cites this paper
• HER2-Based Immunotherapy for Breast Cancer

  2018cites this paper
• Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice.

  2017cites this paper
• Identification of tumor antigens in malignant mesothelioma

  2017cites this paper
• [The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].

  2017cites this paper
• Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control

  2017cites this paper
• La réponse immunitaire anti-tumorale dans le cancer du sein : état des lieux et perspectives thérapeutiques

  2017cites this paper
• Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer

  2017cites this paper
• The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy

  2017cites this paper
• Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer.

  2017cites this paper
• 6.01 – Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R

  2017cites this paper
• Progress in Vaccine Therapies for Breast Cancer.

  2017cites this paper
• Engineered T cells: the promise and challenges of cancer immunotherapy

  2016cites this paper
• Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18

  2016cites this paper
• A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA

  2016cites this paper
• Circulating Anti-Matrix Metalloproteinase-7 Antibodies May Be a Potential Biomarker for Oral Squamous Cell Carcinoma.

  2016cites this paper
• Protein microarray applications: Autoantibody detection and posttranslational modification

  2016cites this paper
• Immunotherapeutic Modalities in the Treatment of Head & Neck Squamous Cell Carcinoma

  2016cites this paper
• Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

  2016cites this paper
• A therapeutic Her 2 / neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her 2 / neu-expressing tumor in HLA-A 2 transgenic mice

  2016cites this paper
• A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice

  2016cites this paper
• HER-2-based design of pertuzumab mimetic peptides

  2015cites this paper
• Detection of Biomarkers for Different Diseases on Biosensor Surfaces Part II

  2015cites this paper
• The Role of Mechanism of Action of CD200:CD200R1 Interaction in Breast Cancer

  2015cites this paper
• Tumor associated antigens and its potential use in cancer therapy

  2015cites this paper
• Breast Cancer Immunotherapy.

  2015cites this paper
• Utility of autoantibodies as biomarkers for diagnosis and staging of neurodegenerative diseases.

  2015cites this paper
• Dendritic Cell Targeting Vaccines

  2015cites this paper
• Metformin Effects on Malignant Cells and Healthy PBMC; The Influence of Metformin on the Phenotype of Breast Cancer Cells

  2015cites this paper
• Cancer vaccines

  2015cites this paper
• HER2-directed therapy: current treatment options for HER2-positive breast cancer

  2015cites this paper
• Linear epitopes that generate anti-HER-2 antibody responses with trastuzuab- (herceptin) like biological activity

  2014cites this paper
• Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer

  2014cites this paper
• Anti-cancer mechanisms of the natural plant derived compound, Withaferin A in HER-2/neu breast cancer

  2014cites this paper
• SA-4-1BBL as a platform to develop adjuvant systems for prophylactic and therapeutic vaccines.

  2014cites this paper
• Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer

  2014cites this paper
• Comparison of Immunity in Mice Cured of Primary/Metastatic Growth of EMT6 or 4THM Breast Cancer by Chemotherapy or Immunotherapy

  2014cites this paper
• Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice

  2014cites this paper
• Detection of tumor-associated antigens in culture supernatants using autoantibodies in sera from patients with bladder cancer.

  2014cites this paper
• Engineering DNA Vaccines for Cancer Therapy

  2014cites this paper
• Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer.

  2014cites this paper
• Recent advances in the development of breast cancer vaccines

  2014cites this paper
• The immune system and inflammation in breast cancer.

  2014cites this paper
• CD40L Gene Therapy for Solid Tumors

  2014cites this paper
• Serum prognostic biomarkers in head and neck cancer patients

  2014cites this paper
• HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

  2014cites this paper
• Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes

  2014cites this paper
• Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

  2013cites this paper
• Caractérisation biochimique et fonctionnelle de nouveaux anticorps monoclonaux anti-galectine-9 en vue d'applications diagnostiques et thérapeutiques

  2013cites this paper
• Recognized by Trastuzumab on the Generation of Peptide Mimics of the Epitope

  2013cites this paper
• Vaccine Mediates Superior Antitumor Factor Receptor-2 B Cell Epitope Peptide A Chimeric Multi-Human Epidermal Growth

  2013cites this paper
• DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice

  2013cites this paper
• Identification of Relevant Conformational Epitopes on the HER2 Oncoprotein by Using Large Fragment Phage Display (LFPD)

  2013cites this paper
• The identification of diagnostic serological autoantibodies for Cutaneous Melanoma

  2013cites this paper
• Ex vivo imaging immune cell interactions in T cell vaccine-induced immunity and CD8+CD25+ T regulatory cell-mediated immune suppression

  2013cites this paper
• Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

  2013cites this paper
• Antitumor Immunity and Dietary Compounds

  2013cites this paper
• Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling

  2013cites this paper
• Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

  2012cites this paper
• T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors

  2012cites this paper
• Recent Trends and Advances in Immunodiagnostics of Solid Tumors

  2012cites this paper
• Targeting Molecular Pathways for Prevention of High Risk Breast Cancer: A Model for Cancer Prevention

  2012cites this paper
• Cancer Therapy Using Viral- and Bacterial Proteins, as Vectors for Vaccines or as Carriers of Cytostatics

  2012cites this paper
• Therapeutic Breast Cancer Vaccines

  2012cites this paper
• In silico design and performance of peptide microarrays for breast cancer tumour auto-antibody testing

  2012cites this paper
• Tumor‐induced changes in the phenotype of blood‐derived and tumor‐associated T cells of early stage breast cancer patients

  2012cites this paper
• In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer

  2012cites this paper